JP2016535772A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535772A5 JP2016535772A5 JP2016551466A JP2016551466A JP2016535772A5 JP 2016535772 A5 JP2016535772 A5 JP 2016535772A5 JP 2016551466 A JP2016551466 A JP 2016551466A JP 2016551466 A JP2016551466 A JP 2016551466A JP 2016535772 A5 JP2016535772 A5 JP 2016535772A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- hydrogen atom
- methyl
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013232571 | 2013-11-08 | ||
| JP2013232571 | 2013-11-08 | ||
| JP2014128562 | 2014-06-23 | ||
| JP2014128562 | 2014-06-23 | ||
| PCT/JP2014/080005 WO2015068856A1 (en) | 2013-11-08 | 2014-11-05 | Pyrazole for the treatment autoimmune disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535772A JP2016535772A (ja) | 2016-11-17 |
| JP2016535772A5 true JP2016535772A5 (https=) | 2017-09-21 |
| JP6412148B2 JP6412148B2 (ja) | 2018-10-24 |
Family
ID=51999482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551466A Active JP6412148B2 (ja) | 2013-11-08 | 2014-11-05 | 自己免疫疾患治療のためのピラゾール |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9321757B2 (https=) |
| EP (1) | EP3066094B1 (https=) |
| JP (1) | JP6412148B2 (https=) |
| CN (1) | CN105899505B (https=) |
| BR (1) | BR112016010041B1 (https=) |
| CA (1) | CA2929316C (https=) |
| EA (1) | EA201690952A1 (https=) |
| ES (1) | ES2777123T3 (https=) |
| TW (1) | TW201605847A (https=) |
| UY (1) | UY35821A (https=) |
| WO (1) | WO2015068856A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN105899505B (zh) * | 2013-11-08 | 2018-08-28 | 武田药品工业株式会社 | 用于治疗自身免疫病症的吡唑 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| EP3416967B1 (en) * | 2016-02-18 | 2022-02-09 | F. Hoffmann-La Roche AG | Therapeutic compounds, compositions and methods of use thereof |
| WO2017170830A1 (ja) * | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
| CN106317952B (zh) * | 2016-08-19 | 2018-03-09 | 福建中烟工业有限责任公司 | 一种增白组合物、其制备方法及用途 |
| JP2019196309A (ja) * | 2016-09-15 | 2019-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| US10414753B2 (en) * | 2016-10-26 | 2019-09-17 | Rigel Pharmaceuticals, Inc. | Amide compounds and method for making and using |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| CN110494434B (zh) | 2017-03-14 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 吡唑并氯苯基化合物、其组合物及其使用方法 |
| WO2018215389A1 (en) | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CA3092625A1 (en) | 2018-04-05 | 2019-10-10 | Merck Patent Gmbh | Heteroaryl compounds as type ii irak inhibitors and uses thereof |
| EP3553061A1 (en) * | 2018-04-12 | 2019-10-16 | Centre National De La Recherche Scientifique (Cnrs) | New inhibitors of bone resorption |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| US12109193B2 (en) | 2018-07-31 | 2024-10-08 | Loxo Oncology Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
| KR102625224B1 (ko) | 2018-10-31 | 2024-01-15 | 주식회사 큐로젠 | 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물 |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US20230125380A1 (en) * | 2019-11-05 | 2023-04-27 | Dermira, Inc. | Topical Compositions Comprising IRAK4 Inhibitors for Use in Treating Dermatological Conditions Characterised by Inflammation |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| CA3186630A1 (en) * | 2020-06-30 | 2022-01-06 | Dermira, Inc. | Irak4 inhibitors and topical uses thereof |
| PH12023500015A1 (en) | 2020-12-30 | 2024-03-11 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| US12187744B2 (en) | 2021-10-29 | 2025-01-07 | Kymera Therapeutics, Inc. | IRAK4 degraders and synthesis thereof |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| JP2025513716A (ja) | 2022-03-23 | 2025-04-30 | ライジェル・ファーマシューティカルズ・インコーポレイテッド | Ｉｒａｋ阻害剤としてのピリミド－２－イル－ピラゾール化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100160324A1 (en) | 2004-12-30 | 2010-06-24 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| CA2668210C (en) * | 2006-10-31 | 2013-03-12 | Schering Corporation | Anilinopiperazine derivatives and methods of use thereof |
| EP2070924A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel |
| AR077033A1 (es) | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| JP2012254939A (ja) * | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| JP6161537B2 (ja) * | 2010-04-07 | 2017-07-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物及び使用の方法 |
| CN105899505B (zh) * | 2013-11-08 | 2018-08-28 | 武田药品工业株式会社 | 用于治疗自身免疫病症的吡唑 |
-
2014
- 2014-11-05 CN CN201480072420.9A patent/CN105899505B/zh active Active
- 2014-11-05 JP JP2016551466A patent/JP6412148B2/ja active Active
- 2014-11-05 BR BR112016010041-7A patent/BR112016010041B1/pt active IP Right Grant
- 2014-11-05 EA EA201690952A patent/EA201690952A1/ru unknown
- 2014-11-05 WO PCT/JP2014/080005 patent/WO2015068856A1/en not_active Ceased
- 2014-11-05 ES ES14805371T patent/ES2777123T3/es active Active
- 2014-11-05 EP EP14805371.3A patent/EP3066094B1/en active Active
- 2014-11-05 UY UY0001035821A patent/UY35821A/es not_active Application Discontinuation
- 2014-11-05 US US14/533,326 patent/US9321757B2/en active Active
- 2014-11-05 TW TW103138324A patent/TW201605847A/zh unknown
- 2014-11-05 CA CA2929316A patent/CA2929316C/en active Active
-
2016
- 2016-04-25 US US15/137,161 patent/US9890145B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535772A5 (https=) | ||
| JP2018519323A5 (https=) | ||
| JP2016536363A5 (https=) | ||
| JP2017502940A5 (https=) | ||
| CA2796967A1 (en) | Heterocyclic derivatives as alk inhibitors | |
| JP2017513894A5 (https=) | ||
| JP2017514830A5 (https=) | ||
| JP2016536364A5 (https=) | ||
| JP2015501799A5 (https=) | ||
| JP2014511869A5 (https=) | ||
| JP2010506825A5 (https=) | ||
| JP2017214387A5 (https=) | ||
| HRP20170112T1 (hr) | Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze | |
| JP2010504280A5 (https=) | ||
| JP2008511683A5 (https=) | ||
| JP2016537389A5 (https=) | ||
| JP7368365B2 (ja) | Ｐ３００／ｃｂｐ ｈａｔ阻害剤及びそれらの使用の方法 | |
| JP2016530322A5 (https=) | ||
| JP2013531074A5 (https=) | ||
| JP2017506237A5 (https=) | ||
| JP2016528273A5 (https=) | ||
| JP2020500916A5 (https=) | ||
| JP2017505293A5 (https=) | ||
| JP2016529235A5 (https=) | ||
| JP2017517538A5 (https=) |